Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, announced that CEO Michael A. Metzger will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 10:30 a.m. PT/ 1:30 p.m. ET. Interested parties can access a live webcast of the fireside chat through the Investor section of Syndax's website, where a replay will also be available temporarily.

News Market Reaction – SNDX

+0.80%

+0.80% Session move

In the trading session that priced this news, SNDX gained 0.80%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT/ 1:30 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-43rd-annual-jp-morgan-healthcare-conference-302343500.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When is Syndax (SNDX) presenting at the 2025 J.P. Morgan Healthcare Conference?

Syndax (SNDX) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PT/ 1:30 p.m. ET.

How can investors watch Syndax's (SNDX) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live webcast of Syndax's presentation through the Investor section of the company's website at www.syndax.com, where a replay will also be available for a time.

Who will represent Syndax (SNDX) at the 2025 J.P. Morgan Healthcare Conference?

Michael A. Metzger, Chief Executive Officer of Syndax, will represent the company at the conference.

What type of presentation will Syndax (SNDX) give at the J.P. Morgan Healthcare Conference?

Syndax will participate in a fireside chat format presentation at the conference.